COLLABORATING TO ACHIEVE UNIVERSAL HEALTH COVERAGE

How the innovative pharmaceutical industry is partnering to ensure innovation and access contribute to global health progress and improve lives everywhere.
CONTENTS

3 – UNIVERSAL HEALTH COVERAGE AND THE SUSTAINABLE DEVELOPMENT GOALS

4 – FROM LAB TO LAST MILE

6 – OUR DIVERSE PARTNERS

6 – DISEASES AND POPULATIONS WE TARGET

7 – OUR GLOBAL REACH

7 – OUR CONTRIBUTION TO THE SDGs REACHES BEYOND HEALTH

8 – UHC2030 PRIVATE SECTOR CONSTITUENCY 5 COMMITMENTS

9 – CASE STUDIES

9 – An Accord for a Healthier World

9 – Gilead Technology Transfers/Licensing Agreements

10 – Novartis Healthy Family Programs

10 – Global Health Innovative Technology (GHIT) Fund

11 – Changing Diabetes® in Children

11 – Sanofi Global Health Unit

12 – MSD for Mothers

12 – Accelerating development and access to an age-appropriate once-daily dispersible HIV treatment for children

13 – Johnson & Johnson Center for Health Worker Innovation

13 – Healthy Heart Africa (HHA) program

14 – Access Accelerated Initiative

14 – Nigerian Cancer Health Fund

15 – City Cancer Challenge (C/Can)

15 – Access to Oncology Medicines (ATOM) Coalition
The Sustainable Development Goals (SDGs) explicitly strive to engage the private sector in addressing the world’s most pressing challenges and emphasize the importance of cross-sector collaborations.

Universal Health Coverage (UHC) is at the heart of the health-related SDGs and the foundation for improving health and well-being for all people at all ages, and for global health security.

Data show that countries with strong health systems centred around primary health care, and especially those that have UHC, were better able to plan mass immunization campaigns and scale up emergency services for patients with COVID-19 while maintaining access to routine and essential services.1

The private sector, as significant providers of health products and services, makes vital contributions to advance UHC and health security. It is a leader in innovation and new products, techniques, and insights that can improve health care, strengthen health systems, and increase efficiencies.

The private sector already provides health products and services for millions of people and communities globally. Most countries have mixed (public and private) health systems. The private sector provides over 60% of health services in some countries.2

The innovative pharmaceutical industry plays a unique role in driving innovation and is part of the solution toward global efforts to achieve UHC.

It supports the efforts of governments and other stakeholders to provide the necessary enabling environments, including through:

- Building health system readiness and resilience together with a life-course approach
- Investing more and investing better to achieve and uphold quality UHC
- Supporting collective public-private collaborations to accelerate progress.

“The innovative pharmaceutical industry plays a unique role within the private sector to accelerate progress toward the Sustainable Development Goals (SDGs). Its past, present, and future medical innovations, combined with pathways to ensure access, bring hope and solutions to improving health around the world. Now, more than ever, coordinated, inclusive, and multistakeholder action is needed to drive innovative solutions to health, social, economic, and environmental challenges.

To help achieve Universal Health Coverage (UHC), innovative pharmaceutical companies support hundreds of collaborations to forge ready and resilient health systems, building healthier communities and stronger economies around the world.”

THOMAS CUENI
Director General, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The innovative pharmaceutical industry brings together a diversity of skills, expertise, and solutions to advance UHC.

It does this not only by developing life-saving and life-enhancing medicines and vaccines, but in partnering to innovate and strengthen the delivery of care while upholding ethics and business integrity standards.

**FROM LAB TO LAST MILE**

The innovative pharmaceutical industry brings together a diversity of skills, expertise, and solutions to advance UHC.

It does this not only by developing life-saving and life-enhancing medicines and vaccines, but in partnering to innovate and strengthen the delivery of care while upholding ethics and business integrity standards.

**DISCOVERING, DEVELOPING, AND DELIVERING MEDICINES AND VACCINES, AND IMPROVING PEOPLE’S HEALTH AROUND THE WORLD.**

Innovative pharmaceutical companies:

- **Today:** Deliver medicines and vaccines that significantly improve people’s lives, bringing medical and economic benefits to healthcare systems and society
- **Tomorrow:** Continue to research and develop (R&D) the next generation of medicines and vaccines for unmet medical needs
- **Our Legacy:** Provide a lasting contribution to global health thanks to widely available and numerous classes of medicines and vaccines. These are the fruit of innovation over decades and have changed disease prevention and treatment paradigms, enabling people to live longer, healthier lives.

**FOSTERING INNOVATION ACROSS THE CONTINUUM OF MEDICAL EDUCATION, PREVENTION, DIAGNOSIS, TREATMENT, AND CARE, AND EXPANDING ACCESS TO QUALITY MEDICINES AND VACCINES THROUGH INNOVATIVE SOLUTIONS, INCLUDING HEALTH FINANCING MECHANISMS.**

**SHARING EXPERTISE AND EXPERIENCE IN TECHNOLOGY AND DIGITAL SOLUTIONS, TRAINING OF HEALTHCARE WORKERS, HUMAN RESOURCES MANAGEMENT, LOGISTICS AND SUPPLY CHAIN MANAGEMENT, AND HEALTH LITERACY AND EDUCATION TO COMMUNITIES.**

*“Investing in vaccines is investing in more than just health. Vaccines can lower health inequities and the burden of care on families and healthcare systems. Yet, COVID-19 disruptions led to 23 million children missing out on their childhood vaccinations and highlighted adults’ vulnerability to infectious diseases. Embedding a life-course immunization approach in a country’s UHC plan is critical to sustain routine childhood coverage, as well as reach people at all stages and ages of life, ensuring more people can benefit from the protection of vaccines throughout their lives.”*  

**MARTHA REBOUR**  
Executive Director, Shot@Life, United Nations Foundation

*Image: © Daniel Victor Narotey*
DISCOVER HOW THE **INNOVATIVE PHARMACEUTICAL INDUSTRY** IS EMBRACING PARTNERSHIPS TO ACCELERATE ACTION ON SDG 3 AND OTHER GLOBAL GOALS

“All countries need to raise domestic resources to increase spending on health and reorient financing mechanisms toward primary healthcare. This will require the push for more meaningful partnerships, empowering local healthcare providers and leveraging innovative solutions to deliver care. We need bold and innovative collaborations to train and retain health care workers, advance new technologies and approaches to expand access, increase efficiencies, and accelerate progress towards UHC.”

**DR. GITHINJI GITAHI**  
Group CEO, Amref Health Africa

“Primary health care is fundamental to delivering essential maternal, newborn, child, and adolescent health services, and represents the cornerstone of Universal Health Coverage. Public private partnerships and leadership of the pharmaceutical industry are critical to accelerate progress towards UHC by ensuring that innovative health technologies and services benefit all populations, including the most vulnerable communities.”

**HELGA FOGSTAD**  
Executive Director, Partnership for Maternal, Newborn and Child Health (PMNCH)

“Noncommunicable diseases (NCDs) are a complex issue that challenge the very limits of health systems around the world. Progress on NCDs relies on achieving UHC. Meaningful progress cannot happen in a silo. Addressing UHC and NCDs means engaging in deep collaboration and conversations across all sectors – public, private, and civil society.”

**DR. HAJIME INOUE**  
Advisor, Health, Nutrition and Population program at the World Bank Group

“Primary health care is fundamental to delivering essential maternal, newborn, child, and adolescent health services, and represents the cornerstone of Universal Health Coverage. Public private partnerships and leadership of the pharmaceutical industry are critical to accelerate progress towards UHC by ensuring that innovative health technologies and services benefit all populations, including the most vulnerable communities.”

**HELGA FOGSTAD**  
Executive Director, Partnership for Maternal, Newborn and Child Health (PMNCH)
**OUR DIVERSE PARTNERS**

Either individually or by combining forces, innovative pharmaceutical companies work in collaboration with global and local stakeholders. They focus on supporting governments in the development of whole-of-society solutions designed to strengthen health systems, improve access to care, and close the equity gap.

To ensure these efforts stand the test of time, companies foster local ownership and design programs according to specific needs and existing system infrastructures.

**WE PARTNER WITH A DIVERSE RANGE OF ACTORS:**

- Governments
- Academia and research institutes
- Multilateral organizations
- Global and local NGOs
- Private foundations or developmental organizations
- Private sector companies, such as other innovative pharmaceutical companies; generic manufacturers; biotech and diagnostic companies; data, technology, and telecom companies; services, logistics, and supply chain providers; health insurers; and more

**THE MOST COMMON PARTNERS WE WORK WITH ARE:**

- **Bill and Melinda Gates Foundation** 20 programs
- **World Health Organization (WHO)** 20 programs
- **US Agency for International Development (USAID)** 12 programs
- **Medicines for Malaria Venture (MMV)** 12 programs
- **UNICEF** 10 programs
- **Bill and Melinda Gates Foundation** 20 programs

Innovative pharmaceutical companies collaborate on...

<table>
<thead>
<tr>
<th>Partners</th>
<th>Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>World Health Organization (WHO)</td>
<td>20 programs</td>
</tr>
<tr>
<td>Multilateral organizations</td>
<td>39 MULTI-COMPANY PROGRAMS</td>
</tr>
<tr>
<td>Global and local NGOs</td>
<td></td>
</tr>
<tr>
<td>Private foundations or developmental organizations</td>
<td></td>
</tr>
<tr>
<td>Private sector companies</td>
<td></td>
</tr>
</tbody>
</table>

**THE POPULATIONS WE SUPPORT BY DISEASE AREA:**

<table>
<thead>
<tr>
<th>Population</th>
<th>People with low incomes</th>
<th>Women</th>
<th>Children</th>
<th>Youth</th>
<th>Marginalized people</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs</td>
<td>17 43 36 12 18</td>
<td>9 25 34 11 25</td>
<td>13 31 35 12 21</td>
<td>8 15 20 11 16</td>
<td>13 12 22 9 14</td>
</tr>
</tbody>
</table>

Whether it is about R&D or complying with regulatory requirements, our industry strongly supports evidence-based approaches, and it strives to apply the same approach to investments in health partnerships. Measuring results helps us show what is working, what is not, and how, together with our partners, we can adapt and scale-up our work.
The innovative pharmaceutical industry discovers, develops, and delivers innovative medicines and vaccines that enable people to live longer, healthier, and more productive lives. In addition to our contribution to innovation, we develop holistic programs and use a range of strategies to support better health for all and progress toward achieving SDG 3. We equally advance SDG 17 to strengthen the means of implementation and global partnership, as well as other goals.

Innovative pharmaceutical companies are also dedicated to addressing environment-related SDGs, including SDG 6 on clean water and sanitation, SDG 12 on responsible production and consumption, and SDG 13 on climate action. Companies are working on initiatives to reduce carbon emissions across their own operations and value chains, invest in renewable electricity and energy efficiency measures, recycle and cut water use, as well as work on bespoke projects that will positively impact the environment.1

All data correct as of April 2023.

1 IFPMA member companies are committed to mitigating the health challenges of climate change, however Global Health Progress hub (globalhealthprogress.org) does not track efforts toward these SDGs yet.
UHC2030 represents a cross-sectoral platform encompassing civil society, governments, and the private sector. As long-term partners in the UHC2030 movement, and as part of the UHC2030 Private Sector Constituency (PSC), IFPMA and our members reiterate the innovative pharmaceutical industry’s commitments to contribute to UHC.

Together with other global health stakeholders, the innovative pharmaceutical industry works to improve health and well-being for all people at all ages and strengthen global health security that serves us all.

The following case studies include examples of IFPMA members’ innovative approaches to R&D and product development as well as innovative access, product supply, and healthcare delivery models, in line with UHC 2030’s PSC statement.

These multistakeholder collaborations strengthen healthcare facilities by:

1. Providing equipment and resources
2. Increasing access to medical products through sustainable affordability approaches and pricing strategies
3. Advancing sustainable financing through both foreign direct investments and blended financing mechanisms for increased domestic resources for health
4. Enhancing regulatory and supply chain regimes
5. Supporting quality training and education for healthcare professionals
6. Engaging communities to increase disease awareness.

The 14 program case studies showcased in this report represent a small segment of the work done by IFPMA member companies. Innovative pharmaceutical companies are currently collaborating on over 250 collaborations with almost 700 diverse partners to support progress toward UHC and the SDGs.

Global Health Progress is an interactive knowledge hub highlighting these collaborations. Global Health Progress also shares information and best practices to support continual learning, drawing on complementary expertise to expand the reach and impact of partnerships.

Find out more: globalhealthprogress.org and ifpma.org

* Data reflects content in Global Health Progress as of 10 March 2023.
* UHC2030 Private Sector Engagement.

Global Health Progress
AN ACCORD FOR A HEALTHIER WORLD

ACTIVE SINCE: 2022

The Accord aims to provide access to Pfizer’s full portfolio for which we have global rights on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world.

PROGRAM OVERVIEW

An Accord for a Healthier World is a first-of-its-kind initiative to enable sustained, equitable access to high-quality, safe, and effective medicines and vaccines with the potential to improve the health of 1.2 billion people living in 45 lower-income countries. Under the Accord, Pfizer has committed to offer the full portfolio for which the company holds global rights on a not-for-profit basis to these countries. By doing so, the Accord aims to provide prevention and treatment options for those impacted by deadly infectious diseases, as well as heart disease, certain cancers, rare and inflammatory diseases, and more. Alongside governments and multi-sector leaders, the Accord will focus on co-creating solutions for faster, more efficient supply pathways for medicines and vaccines as well as strengthening the resources, capabilities, and platforms that can enable quick, yet sustainable access to them, including technical expertise, training, diagnostic capacity, innovative financing, and beyond.

RESULTS AND MILESTONES

In 2022, Rwanda became the first country to receive deliveries of Pfizer patent-protected medicines and vaccines through the Accord, including nine products to help treat or prevent life-threatening infectious and inflammatory diseases, and certain cancers. Together, the Rwandan Ministry of Health and Pfizer are working to provide professional healthcare education and training to support Rwandan medical specialists.

In November 2022, Pfizer deployed its first Global Health Team to Rwanda to help identify opportunities for long-term supply chain optimization.

See Global Health Progress for the full program overview.

GILEAD TECHNOLOGY TRANSFERS/LICENSEING AGREEMENTS

ACTIVE SINCE: 2006

The objective of Gilead’s technology transfers is to ensure that generic versions of Gilead medicines — in their intended composition — reach the patients who need them.

PROGRAM OVERVIEW

Gilead has been involved in licensing to generic manufacturers since 2006 when it granted its first license to HIV patents. Additional license agreements were executed in 2014 for hepatitis C and in 2020 for COVID-19. These agreements support the development and commercialization of high-quality, low-cost medicines in low- and lower-middle income countries (LLMICs). Gilead provides technology transfers to enable generic versions of Gilead medicines to reach the patients who need them. Gilead works with local producers to enable them to conduct large-scale manufacturing, provide manufacturers with assistance to help them ensure product safety and stability, and provide them with support to expand production. These licensees can obtain technology transfers of manufacturing processes for finished products and the production of active ingredients. Licensees are then able to sell active pharmaceutical ingredients to other licensees and set their own pricing for finished products. Royalties paid to Gilead by these generic manufacturers are reinvested into Gilead’s support activities to maintain its voluntary licensing program.

RESULTS AND MILESTONES

Gilead’s innovation and access program has enabled the availability of millions of HIV and viral hepatitis treatments for people in LMICs.

Gilead’s voluntary licensing program for remdesivir has enabled access to the COVID-19 antiviral medicine for more than 8 million people in LMICs.

Gilead was the first innovator company to join the Medicines Patent Pool, a Unitaid-backed organization that works to expand global access to high-quality, low-cost therapy through the licensing of patents.

See Global Health Progress for the full program overview.
**NOVARTIS HEALTHY FAMILY PROGRAMS**

**ACTIVE SINCE:** 2007

Novartis Healthy Family offers an Integrated community health model that builds local, sustainable programs to enhance access to healthcare and medicines in developing countries.

**MEMBER COMPANIES:**

![Novartis Logo]

**STRATEGY:** Community awareness and linkage to care • Health system strengthening • Health service delivery

**SCOPE:** Africa (Kenya) • South East Asia (India) • Western Pacific (Vietnam)

**TARGET POPULATION:** Children • Women • People with low incomes • Marginalized/indigenous people • Rural populations

**AMONG SUPPORTING PARTNERS:**

- Local NGOs
- Global NGOs
- Ministries of health

**PROGRAM OVERVIEW**

The Novartis Healthy Family model is based on six “A’s”: Awareness, Affordability, Adherence, Adaptability, Availability, and Alliances. Novartis recruits and trains locals in remote villages to become “health educators.” They help inform communities about health, disease prevention, and the benefits of seeking timely treatment. Local teams also work with doctors to organize health camps in remote villages – mobile clinics that provide access to screening, diagnosis, and therapies. “Health supervisors” serve as the initiative’s local sales force, interacting with local pharmacies and doctors.

The initiative also offers affordable medications for communicable and non-communicable diseases. These are adapted to local market conditions, and to the diseases most prevalent in the rural areas of each country. To be included in the portfolio, products need to be simple to use and relevant to local patients. The current portfolio includes antibiotics, non-steroidal anti-inflammatory agents, diabetes, hypertension, and dyslipidemia medicines, as well as anti-infectives that can be used in gynecological treatments.

**RESULTS AND MILESTONES**

- The first program (“Arogya Parivar”) was launched in 2007 in India and became self-sustaining in less than three years.
- Given Arogya Parivar’s success in India, Novartis has rolled out similar programs in Vietnam and Kenya. Novartis plans to evolve the portfolio to include more innovative medicines.

See [Global Health Progress](#) for the full program overview.

---

**GLOBAL HEALTH INNOVATIVE TECHNOLOGY (GHIT) FUND**

**ACTIVE SINCE:** 2013

This Japanese-led initiative discovers and advances the development of new health technologies such as drugs, vaccines, and diagnostics for LMICs.

**MEMBER COMPANIES:**

![GHIT Partners Logos]

**STRATEGY:** Drug development and research • Health service delivery

**SCOPE:** Global commitment

**TARGET POPULATION:** Children and youth • Men • Women • People with low incomes

**AMONG SUPPORTING PARTNERS:**

- Global Alliance for TB Drug Development (TB Alliance)
- Drugs for Neglected Diseases Initiative (DNDi)
- Bill and Melinda Gates Foundation
- United Nations Developmental Program (UNDP)

**PROGRAM OVERVIEW**

Japan’s government and its drug industry — the third largest in the world — bring Japan’s technology, innovation, and insights to the development of drugs, vaccines, and diagnostics for the developing world. As the world’s first public-private partnership, the GHIT Fund was established by the Government of Japan, the Bill & Melinda Gates Foundation, and five Japanese leading pharmaceutical companies. By 2018, the partnership extended its membership to 11 partners.

The GHIT Fund provides grants for R&D projects to counteract common global threats to the health of citizens in Japan. Since its inception, the GHIT Fund has facilitated research and development for Neglected Tropical Diseases (NTDs), malaria, tuberculosis (TB), and antimicrobial resistance (AMR).

**RESULTS AND MILESTONES**

- The GHIT Fund has provided over USD 17.7 million in grants to global partnerships developing innovative drugs and vaccines against malaria, TB, and NTDs, including leishmaniasis and Chagas disease.
- The GHIT Fund’s latest investments include funds towards a vaccine that could block the transmission of two species of malaria, a rapid-fire test that can reveal a malaria infection in minutes, and the development of a new TB diagnostic test for HIV-positive patients.

See [Global Health Progress](#) for the full program overview.

---

*Collaborating to Achieve Universal Health Coverage*
CHANGING DIABETES® IN CHILDREN

ACTIVE SINCE: 2009

The Changing Diabetes® in Children (CDiC) program ensures care and life-saving medicine for children with type 1 diabetes (T1D) in LMICs. This includes free life-saving medicine and supplies for people up to 25 years of age.

SANOFI GLOBAL HEALTH UNIT

ACTIVE SINCE: 2021

Sanofi Global Health is a newly formed non-profit unit within Sanofi. It sets out to improve the lives of underserved populations through innovative, inclusive healthcare models and partnerships that deliver sustainable impact.

PROGRAM OVERVIEW

CDiC is a public-private partnership launched by Novo Nordisk in 2009. In each country where the program is active, it is implemented by a group of local partners in close collaboration with national health systems. The program aims to bring all elements of necessary diabetes care closer to the children who need it, while building capacity for the diagnosis and treatment of children with T1D at both community and country levels. The program has four main components:
- Ensuring comprehensive patient education through equipment and materials
- Strengthening healthcare professional capacity with trainings on T1D diagnosis and treatment
- Bringing care closer to the people who need it by promoting accessible health facilities
- Ensuring access to insulin and supplies through donations and supply chain strengthening.

RESULTS AND MILESTONES

- Since its launch in 2009, CDiC has trained more than 24,000 healthcare providers, established 360+ type 1 diabetes clinics, delivered over 3.8M vials, pens, and cartridges of insulin, and reached over 41,000 children in 26 LMICs.
- At the launch of its Defeat Diabetes social responsibility strategy in 2019, Novo Nordisk set an ambitious new goal to reach 100,000 vulnerable children and young people living with T1D by 2030.
MSD FOR MOTHERS
ACTIVE SINCE: 2011
This USD 650 million global initiative helps ensure that women have access to two of the most powerful means to end preventable maternal deaths: quality maternity care and modern contraception.

MEMBER COMPANIES:

STRATEGY:
Community awareness and linkage to care • Health system strengthening • Financing • Medicine donations • Health service delivery – Prevention • Health service delivery – Treatment

SCOPE:
Global commitment

TARGET POPULATION:
Women • Marginalized/indigenous people

AMONG SUPPORTING PARTNERS:
→ 165 grantees and collaborators around the globe

PROGRAM OVERVIEW
MSD for Mothers empowers women to make informed choices about contraceptives and the quality care they need for healthy pregnancies and safe childbirth. It also equips health care providers with the skills, tools, and technologies needed to deliver high-quality services.

Working with governments; NGOs; patient groups; physician, nursing, and midwife associations; entrepreneurs; UN agencies; research institutions; and others, MSD takes a comprehensive and collaborative approach for sustainably strengthening health systems to increase access to quality maternal health care and achieve UHC by:

→ Supporting quality accreditation of local health providers
→ Developing and deploying private sector innovations
→ Incorporating local and community-led solutions.

Under this initiative, MSD works on several projects that aim to strengthen local health systems through multi-sector collaboration, expand the availability of health services to reach more people, help patients safeguard against catastrophic health expenditures, and ensure the quality and sustainability of maternal healthcare provision.

RESULTS AND MILESTONES
→ Since its inception, MSD for Mothers has reached more than 20 million women through programs promoting safe, high-quality, respectful care, and has supported more than 200 strategic investments with more than 165 grantees and collaborators around the globe.
→ In 2021, MSD for Mothers launched a new global initiative — Strengthening Systems for Safer Childbirth — to save women’s lives via locally-driven solutions.

See Global Health Progress for the full program overview.

ACCELERATING DEVELOPMENT AND ACCESS TO AN AGE-APPROPRIATE ONCE-DAILY DISPERSIBLE HIV TREATMENT FOR CHILDREN
ACTIVE SINCE: 2007
The project speeds up research, development, and the introduction of optimized generic pediatric formulations of dolutegravir (DTG) for children living with HIV in resource-limited settings.

MEMBER COMPANIES:

STRATEGY:
Manufacturing • Drug development and research • Health service delivery – Treatment

SCOPE:
Africa (47 countries) • Americas (Bolivia, El Salvador, Haiti, Honduras, Nicaragua) • Eastern Mediterranean (13 countries) • Europe (Kyrgyzstan, Tajikistan, Ukraine, Uzbekistan) • South East Asia (9 countries) • Western Pacific (12 countries)

TARGET POPULATION:
Children and youth

AMONG SUPPORTING PARTNERS:
→ Clinton Health Access Initiative (CHAI)
→ Unitaid
→ Mylan Laboratories Ltd (part of the Viatris Group)
→ Macleods Pharmaceuticals Limited

PROGRAM OVERVIEW
A fragmented pediatric HIV market hinders the introduction and uptake of new formulations. Drug research and development for children living with HIV continues to lag considerably behind advances in adult treatment. Insufficient market incentives and technical complexity in the manufacturing process also means that pediatric drug development does not get the priority it deserves.

This collaboration between ViiV Healthcare, CHAI, and Unitaid accelerates generic development, registration, and distribution of pediatric formulations of an antiretroviral medicine DTG through the transfer of dispersible tablet technology. This builds on ViiV Healthcare’s work to enable generic pharmaceutical companies to manufacture and sell generic versions of this medicine in resource-limited settings through existing royalty-free voluntary licensing agreements that have been granted both directly and via the Medicines Patent Pool. These agreements enable generic manufacturers to develop pediatric formulations in 121 countries, covering 99% of children living with HIV in LMICs.

RESULTS AND MILESTONES
→ As of December 2022, 73 countries were being supplied with generic pediatric DTG dispersible tablets — just two years after the first generic formulation received tentative US FDA approval. This includes all 10 countries with the highest incidence of pediatric HIV.
→ Following the success of this public-private partnership, work is underway between ViiV, CHAI, and Unitaid to accelerate generic development, registration, and supply of an additional DTG-based pediatric treatment, which received US FDA approval and a Committee for Medicinal Products for Human Use (CHMP) positive opinion in 2022. This is the WHO-recommended fixed dose combination dispersible tablet of DTG with abacavir and lamivudine (ALD).

See Global Health Progress for the full program overview.
JOHNSON & JOHNSON CENTER FOR HEALTH WORKER INNOVATION

ACTIVE SINCE: 2019

The Center is tasked with guiding a USD 250 million, 10-year commitment from the Johnson & Johnson Foundation and the Johnson & Johnson Family of Companies to support one million health workers reach 100 million people by 2030.

MEMBER COMPANIES:

- Johnson & Johnson

PROGRAM OVERVIEW

The Center was founded to take on two of the toughest barriers to achieving UHC and the SDGs — closing a 10 million health worker shortage and equipping health workers to thrive. The Center leverages a people-first model, focusing on equipping health workers across the globe with the skills, resources, and support they need to improve quality of care and strengthen community-based health systems.

Championing global health equity is key to the Center’s mission and a core priority of Johnson & Johnson’s ESG strategy. Frontline health workers are often the first and only link between communities and health systems. With half the world lacking access to basic, essential health services, supporting health workers and rebuilding primary healthcare, which has been underfunded for decades, will be critical to achieving global health priorities.

RESULTS AND MILESTONES

- By the end of 2022, the Center’s programming reached over 755,000 frontline health workers, primarily nurses, and community health workers in 2021 alone — already 74% of its 10-year 2030 target. This is primarily a result of the reach of J&J’s digital health programming.
- J&J is working to recalibrate its targets for the years ahead in line with its mission to achieve health equity and access to health for everyone, everywhere.

See Global Health Progress for the full program overview.

HEALTHY HEART AFRICA (HHA) PROGRAM

ACTIVE SINCE: 2014

The HHA program is committed to tackling hypertension and the increasing burden of cardiovascular disease. Its ambition is to reach 10 million people with elevated blood pressure across Africa by 2025.

MEMBER COMPANIES:

- AstraZeneca

PROGRAM OVERVIEW

HHA partners with local stakeholders, including public, private, and faith-based facilities, to integrate blood pressure screening and hypertension treatment into routine care, ultimately developing interventions that are optimized to address local challenges on a sustainable basis. HHA supports local health systems by increasing awareness of the symptoms and risks of hypertension, training healthcare providers, and activating healthcare facilities. The program also offers health education, screening, and reduced-cost treatment and control, as applicable.

From 2016-2021, AstraZeneca collaborated with PEPFAR to integrate HHA’s hypertension services into existing HIV platforms. Hypertension was used as a stigma-free entry point to find and reach those who need HIV services too. In 2023, HHA’s public-private partnership model will grow to include existing health platforms in an additional 10 African countries over two years.

RESULTS AND MILESTONES

- Since screening started in 2015, HHA has conducted over 32 million blood pressure screenings and activated over 1,200 healthcare facilities in Africa to provide hypertension services and facilitate end-to-end disease management in nine countries (data from December 2022).
- Over the same period, HHA has trained over 10,600 healthcare workers to provide education and awareness, screening, and treatment services for hypertension.

See Global Health Progress for the full program overview.
ACCESS ACCELERATED INITIATIVE

ACTIVE SINCE: 2017

Access Accelerated brings together life science companies to collectively tackle the growing burden of non-communicable diseases (NCDs) in LMICs and support progress toward the SDGs.

MEMBER COMPANIES:

- Bristol-Myers Squibb
- Ipsen
- JSI Research and Training Institution
- Lilly
- MSF
- PATH
- IPF
- Japan Tobacco International
- Novartis
- Novo Nordisk
- Roche
- Tokyo
- UCB
- Fabion
- Astellas

STRATEGY:

- Health service delivery
- Community awareness and linkage to care
- Health system strengthening
- Supply chain
- Financing
- Regulation and legislation

SCOPE:

Global commitment

AMONG SUPPORTING PARTNERS:

- World Bank
- RTI International
- Boston University

PROGRAM OVERVIEW

Access Accelerated is a unique cross-industry collaboration that reduces barriers to sustainable and scalable solutions to NCD prevention, treatment, and care in LMICs. They bring global reach and local expertise in partnership with countries, civil society, multilaterals, and NGOs to support cross-sectoral dialogue and drive health systems strengthening in alignment with UHC objectives and priorities.

The World Bank Group and Access Accelerated have been working to advance joint action in-country across three areas:

- Generating high-level evidence on the economic impact of NCDs to make the case for national health policies that can be integrated into countries’ national UHC agendas
- Accelerating public and private investment in NCD prevention, treatment, and care through a portfolio of projects that inform national scale-up and support innovative financing for NCDs
- Optimizing public-private partnership engagement for impact, tracking progress against a results-based monitoring and evaluation system that facilitates evidence-based decision making to guide future NCD programming.

RESULTS AND MILESTONES

The partnership has supported the World Bank on 40+ projects across 36 LMICs by catalyzing new public investment in NCDs and informing USD 2.1 billion in health system investments.

From 2017 to 2022, Access Accelerated also partnered with NGOs, City Cancer Challenge, NCD Alliance, PATH, and the World Heart Federation to support countries to improve access to NCD care.

See Global Health Progress for the full program overview.

NIgerIAN CANCER HEALTH FUND

ACTIVE SINCE: 2020

The Nigeria Cancer Health Fund is an innovative way to ensure the affordability of cancer treatments for patients at treatment centers and is a key part of the nation’s efforts to achieve UHC.

MEMBER COMPANIES:

- Roche

STRATEGY:

Financing • Health service delivery • Treatment

SCOPE:

Africa (Nigeria)

TARGET POPULATION:

People with low incomes

AMONG SUPPORTING PARTNERS:

- International Finance Corporation (IFC)
- Healthcare Federation of Nigeria
- Nigeria National Health Insurance Scheme

PROGRAM OVERVIEW

Health insurance in Nigeria is not widespread and does not offer comprehensive cancer care coverage. Many cancer patients have to go without necessary treatments or begin their medical treatment but stop because they cannot afford the out-of-pocket costs associated with their cancer care.

In 2020, Roche led a private-sector coalition which, with the support of the International Finance Corporation (IFC) and Nigerian public authorities, led to the creation of the Nigerian Cancer Health Fund (CHF). The CHF’s goal is to enable standard of care cancer treatment to underprivileged populations regardless of their ability to pay, and to strengthen the national cancer care ecosystem by improving quality of services. The CHF provides access to funding of up to USD 4,865 for treatments, chemotherapy, and radiation therapy services for people with breast, cervical, and prostate cancers. It is being piloted in designated centers across the country.

RESULTS AND MILESTONES

- Since 2020, approximately USD 4 million has been allocated, offering the potential to provide comprehensive care for people with breast, prostate, and cervical cancers.
- There are six public health institutions involved in the pilot phase, one in each geopolitical zone of the country.

See Global Health Progress for the full program overview.
CITY CANCER CHALLENGE (C/CAN)

ACTIVE SINCE: 2017

C/Can supports cities around the world to improve access to quality, equitable cancer care by building community-led solutions, supporting health system strengthening, and ensuring local ownership.

MEMBER COMPANIES:
- AstraZeneca
- ACCESS Healthcare
- AMGEN
- astellas
- Bristol Myers Squibb
- sanofi
- Pfizer
- Roche

SCOPE:
- Community awareness and linkage to care
- Health system strengthening
- Health service delivery - Treatment
- Health service delivery - Prevention
- Health service delivery - Screening
- Health service delivery - Diagnosis

STRATEGY:
- Global commitment

AMONG SUPPORTING PARTNERS:
- International Finance Corporation (IFC) - World Bank
- Clinton Health Access Initiative
- United Nations Institute for Training and Research (UNITAR)
- World Health Organization (WHO)

PROGRAM OVERVIEW

C/Can supports cities achieve better cancer care by implementing changes that can be scaled up and replicated across health services. The initiative is based on the premise that cities provide a unique ecosystem to test and drive innovation in cancer care — meeting people’s needs from the ground up.

The C/Can model invests in enhancing connections between people, policies, and processes to build capacity and resilience. It convenes policy makers, healthcare providers, patient groups, and partners, creating communities to support the journey to self-reliance. Cities apply to join C/Can and are considered based on their commitment to fighting cancer, alongside other criteria. Once a city is accepted, they will work with C/Can to identify and engage stakeholders, assess their needs, develop solutions, and execute and sustain projects to improve cancer.

RESULTS AND MILESTONES

- There are 13 cities working with C/Can on five areas of action: improving health information systems, developing health workforce capacity, catalyzing health financing, strengthening leadership and governance, and strengthening health service delivery.
- A new call for city applications will be launched in 2023.

See Global Health Progress for the full program overview.

ACCESS TO ONCOLOGY MEDICINES (ATOM) COALITION

ACTIVE SINCE: 2022

The ATOM Coalition is an innovative partnership that leads global collective action to increase access to life-saving cancer diagnostics, medicines, and services in low- and lower-middle-income countries (LLMICs).

MEMBER COMPANIES:
- AstraZeneca
- Bristol Myers Squibb
- GILEAD
- NOVARTIS
- Roche

SCOPE:
- The Union for International Cancer Control (UICC)
- Medicines Patent Pool (MPP)
- Access to Medicine Foundation
- PATH
- Project Echo
- ASCO

STRATEGY:
- Community awareness and linkage to care
- Health system strengthening
- Supply chain
- Financing
- Regulation and legislation
- Drug development and research
- Licensing agreements
- Health service delivery - Treatment
- Health service delivery - Diagnosis

AMONG SUPPORTING PARTNERS:
- The Union for International Cancer Control (UICC)
- Medicines Patent Pool (MPP)
- Access to Medicine Foundation
- PATH
- Project Echo
- ASCO

PROGRAM OVERVIEW

The ATOM Coalition was launched on the sidelines of the 75th World Health Assembly (WHA75) by UICC and its partners. It brings together more than 30 expert organizations from civil society, the public sector, and private sector in the shared ambition to reduce suffering and deaths caused by cancer in LLMICs. It will do this by increasing access to quality-assured essential cancer medicines and the capacity to use these medicines appropriately.

In the first phase of operations (4-5 years), the ATOM Coalition will support the implementation of intensive coordinated capacity building activities in five to 10 countries, expanding to other LLMICs over time. It will also focus on increasing access to medicines in 46 countries classified as LLMICs. Priority will be placed on medicines on the WHO Essential Medicines List (EML) or those likely to be included in the future that treat cancers with the highest incidence-to-mortality rate in LLMICs.

RESULTS AND MILESTONES

- The ATOM Coalition Medicines Expert Advisory Group has put forward a priority list of 17 generic and biosimilar medicines for cancer.
- Under ATOM, Novartis granted the MPP a non-exclusive licence for nilotinib — a treatment for chronic myeloid leukemia on the WHO EML — becoming the first company to sign a non-exclusive voluntary license for an oncology medicine.

See Global Health Progress for the full program overview.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.

gfpm.org

GLOBAL HEALTH PROGRESS
Global Health Progress is an interactive knowledge hub highlighting over 250 collaborations between the innovative pharmaceutical industry and almost 700 diverse partners. These collaborations advance Universal Health Coverage and the Sustainable Development Goals in low- and middle-income countries.

globalhealthprogress.org